Research Article Details
| Article ID: | A25484 |
| PMID: | 21778625 |
| Source: | Nihon Ronen Igakkai Zasshi |
| Title: | [Organs related to glucose metabolism and aging in animal models]. |
| Abstract: | The incidence of type 2 diabetes and metabolic diseases increases with age. Clarification of the underlying mechanisms in age-dependent worsening of such metabolic disorders is crucial for developing more effective strategies for prevention and treatment. However, due to limitations in studying aging-related changes, especially at the tissue level in humans, investigations with adequate animal models are important. Therefore, we investigated 2 inbred lines of mouse, the Nagoya-Shibata-Yasuda (NSY) mouse and the Fatty Liver Shionogi (FLS) mouse. By analyzing NSY mice, which spontaneously develop type 2 diabetes mellitus through impaired insulin secretion and insulin resistance in an age dependent manner, we demonstrated that environmental factors, including infant nutritional condition, modified aging-related metabolic changes, and the effect of genetic components on glucose metabolism, vary according to age. In FLS mice which developed non-alcoholic steatohepatitis with normal feed, accumulation of hepatic lipids caused by reduced VLDL secretion progressed to hepatic inflammation and fibrosis, which was ameliorated by vector-induced hepatic expression of microsomal triglyceride transfer protein, a key molecule for VLDL secretion. In addition, the glucose intolerance of this mouse exhibited 2 different phases: age-related deterioration due to worsening of insulin sensitivity up to 6 months, followed by time-dependent amelioration owing to increased capacity of insulin secretion and β-cell mass thereafter, suggesting slow adaptive β-cell expansion in this model. These results indicate that age-related metabolic changes are an integral part of multiple organ dysfunctions, each of which has a different period of worsening, and which collectively leads to disease. |
| DOI: | 10.3143/geriatrics.48.127 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |